Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis describes new PCSK9 inhibitors

June 18, 2020

Hyundai Pharmaceutical presents phase I data for GPR40 agonist HD-6277 in type 2 diabetes

June 18, 2020

New PCSK9 inhibitors discovered at Novartis

June 17, 2020

MK-1092 demonstrates safety and promising glucose-lowering activity

June 17, 2020

Staten begins first-in-human study of STT-5058 for hypertriglyceridemia

June 17, 2020

FDA approves Lyumjev for type 1 and type 2 diabetes

June 16, 2020

Favorable safety, pharmacodynamic activity seen with FT-4202 in phase I study

June 16, 2020

MT-7117 enters phase III for erythropoietic protoporphyria and X-linked protoporphyria

June 16, 2020

Neurocrine Biosciences reports positive results with crinecerfont in congenital adrenal hyperplasia

June 16, 2020

Identification of oral hydroxpyridinone iron chelator for the treatment of iron overload

June 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...